Value of the Run-In Period to Evaluate the Safety of Conventional Trypanocidal Treatment: A Subanalysis of a Colombian Randomized Clinical Trial
The American Journal of Tropical Medicine and Hygiene · 03.06.2026 · 114 (6) · 1148-1156
DOI: 10.4269/ajtmh.25-0198 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The American Journal of Tropical Medicine and Hygiene, erschienen am 03.06.2026. Verfasst von Juan Carlos Villar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Facultad de Ciencias de la Salud, Universidad Autónoma de Bucaramanga, Bucaramanga, Colombia. Hauptthemen laut MEDLINE: Trypanocidal Agents, Nitroimidazoles, Nifurtimox, Chagas Disease. Die Arbeit nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
When testing poorly tolerated or long-term treatments, including a run-in phase enhances clinical trial efficiency and internal validity by selecting more adherent participants. This report describes the adherence and tolerance of Colombian participants in EQUITY (a randomized, concealed, parallel-group, placebo-controlled trial testing nifurtimox and benznidazole among Trypanosoma cruzi –seropositive adults without cardiomyopathy). Our design included a 10-day, single-blind, placebo run-in phase. On completion, willing participants reporting good adherence (≥80%) and tolerance were randomized to any five 120-day, blinded treatments: four with either active medication, each given as 120-day half dose or 60-day full dose (followed/preceded by a randomly allocated 60-day placebo treatment), or a 120-day placebo. Side effects were compared after the run-in (day 0) between excluded and enrolled participants, and between those randomized to active medications or placebo 20 days after starting each treatment period (days 20/80). Those excluded (44/351, 12.5%) more often reported gastrointestinal (15.9/4.6%), nonspecific (13.7/4.2%), and musculoskeletal symptoms (9.1/1.6%) than those randomized. Participants given nifurtimox ( n = 84) or benznidazole ( n = 86) versus placebo ( n = 126) on day 20 reported more nonspecific (15.5/10.5/4.8%, respectively) or cutaneous side effects (6.0/12.8/3.2%). When starting active treatments (transition OFF–ON, n = 171 and n = 61 in first and second 60-day treatment periods), more participants reported emerging-worsening than receding-ending side effects (49/13 and 15/5, respectively). Despite inducing a nocebo effect, the run-in phase highlighted more closely related side effects, strengthening causal inference and informing adherence and tolerance to conventional trypanocides.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Facultad de Ciencias de la Salud, Universidad Autónoma de Bucaramanga, Bucaramanga, Colombia.
- Subdirección de Investigaciones, Fundación Cardioinfantil - Instituto de Cardiología, Bogotá, Colombia.
Zitieren
APA
Villar, J. C., Arango, H., Sáenz-Pérez, L. D., & Camacho, A. (2026). Value of the Run-In Period to Evaluate the Safety of Conventional Trypanocidal Treatment: A Subanalysis of a Colombian Randomized Clinical Trial. The American Journal of Tropical Medicine and Hygiene, 114(6), 1148-1156. https://doi.org/10.4269/ajtmh.25-0198
Vancouver
Villar JC, Arango H, Sáenz-Pérez LD, Camacho A. Value of the Run-In Period to Evaluate the Safety of Conventional Trypanocidal Treatment: A Subanalysis of a Colombian Randomized Clinical Trial. The American Journal of Tropical Medicine and Hygiene. 2026;114(6):1148-1156. doi:10.4269/ajtmh.25-0198
BibTeX
@article{Villar2026,
author = {Villar, Juan Carlos and Arango, Helena and Sáenz-Pérez, Luis David and Camacho, Antonia},
title = {Value of the Run-In Period to Evaluate the Safety of Conventional Trypanocidal Treatment: A Subanalysis of a Colombian Randomized Clinical Trial},
journal = {The American Journal of Tropical Medicine and Hygiene},
year = {2026},
volume = {114},
number = {6},
pages = {1148--1156},
doi = {10.4269/ajtmh.25-0198}
}
EUVIMED